| 1.305 -0.005 (-0.38%) | 09-08 10:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.65 | 1-year : | 1.79 |
| Resists | First : | 1.41 | Second : | 1.53 |
| Pivot price | 1.37  |
|||
| Supports | First : | 1.21 | Second : | 1 |
| MAs | MA(5) : | 1.29  |
MA(20) : | 1.39 |
| MA(100) : | 1.58 |
MA(250) : | 1.68 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.3 | D(3) : | 31.1 |
| RSI | RSI(14): 39.8 | |||
| 52-week | High : | 3.81 | Low : | 0.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IBIO ] has closed above bottom band by 27.6%. Bollinger Bands are 19.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.34 | 1.34 - 1.35 |
| Low: | 1.26 - 1.27 | 1.27 - 1.28 |
| Close: | 1.3 - 1.31 | 1.31 - 1.32 |
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
Fri, 04 Sep 2026
Ibio Stock Price Forecast. Should You Buy IBIO? - StockInvest.us
Fri, 04 Sep 2026
iBio, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Fri, 04 Sep 2026
Hundreds of millions of new shares on ballot at iBio (IBIO) - Stock Titan
Fri, 04 Sep 2026
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Thu, 03 Sep 2026
iBio, Inc. Common Stock (NASDAQ: IBIO) Share Price, IBIO Stock News, IBIO Share Price & Updates - Kalkine
Thu, 03 Sep 2026
iBio, Inc. (NASDAQ:IBIO) Receives Average Rating of "Buy" from Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 5.211e+007 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 5,380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.949e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -30 % |
| Return on Assets (ttm) | 138 % |
| Return on Equity (ttm) | -30.9 % |
| Qtrly Rev. Growth | 100000 % |
| Gross Profit (p.s.) | -77.52 |
| Sales Per Share | -50.94 |
| EBITDA (p.s.) | 77519.4 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.75 |
| Dividend | 0 |
| Forward Dividend | 5.03e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|